Brain scans may help choose the right psychosis drug faster

NCT ID NCT07483294

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 120 people having their first episode of psychosis. They get brain scans and then take either risperidone or aripiprazole for 12 weeks. The goal is to see if brain scan patterns can predict who will respond well to which drug, potentially personalizing treatment early on.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

risperidone and aripiprazole

What this could lead to

If successful, this could lead to a way to predict which medication works best for a person with early psychosis, speeding up recovery and reducing trial-and-error.

What could go wrong

This is an early-stage observational study, not a treatment trial. The brain scan method may not reliably predict response, and results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSYCHOSIS; ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychotic disorder Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Zucker Hillside Hospital

    RECRUITING

    Glen Oaks, New York, 11004, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••